This is the authors' abstract. We don't add key points for this paper.
Lebrikizumab treatment was associated with improved lung function. Patients with high pretreatment levels of serum periostin had greater improvement in lung function with lebrikizumab than did patients with low periostin levels. (Funded by Genentech; ClinicalTrials.gov number, NCT00930163 .).
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Corren et al. (2011) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: